CD274 and gastric cancer: For gastric cancer (GC) and gastroesophageal junction (GEJ) cancer, the initial phase Ib trial KEYNOTE‐012 showed 22% ORR in patient with PD‐L1 + advanced GC and triggered the initiation of further trials.43